Physician profile
Ryan W Schafer
NPI 1780650606
$3,570.52
in general payments reported to CMS, 2019-2025
34 companies · $343 in 2025
The $343 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $757 · 2021: $878 · 2022: $397 · 2023: $264 · 2024: $259 · 2025: $343.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $866.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $865.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $713.89 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $522.26 | 2019-2023 | Emgality, Jardiance, Trulicity |
| Takeda Pharmaceuticals U.S.A., INC. | $446.81 | 2019-2024 | Trintellix |
| Pfizer INC. | $305.61 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $223.83 | 2019 | |
| Boston Scientific Corporation | $136.88 | 2025 | Intracept, Watchman Access System |
| Bayer Healthcare Pharmaceuticals INC. | $132.86 | 2021-2025 | |
| Collegium Pharmaceutical, INC. | $122.85 | 2019-2022 | |
| Pacira Therapeutics, INC. | $111.88 | 2019-2020 | |
| Alnylam Pharmaceuticals INC. | $100.02 | 2021-2025 | Givlaari |
| Amgen INC. | $96.18 | 2019-2022 | |
| Phathom Pharmaceuticals, INC. | $72.83 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $70.46 | 2020-2024 | Airsupra, Breztri |
| Teva Pharmaceuticals USA, INC. | $48.09 | 2020-2022 | |
| Supernus Pharmaceuticals, INC. | $46.65 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $41.91 | 2019 | |
| Allergan, INC. | $37.08 | 2020 | |
| Abbvie INC. | $33.45 | 2021 | |
| Ironwood Pharmaceuticals, INC | $33.25 | 2020 | |
| Eisai INC. | $28.25 | 2020-2022 | |
| Virtus Pharmaceuticals LLC | $27.96 | 2021 | |
| Merck Sharp & Dohme LLC | $26.60 | 2020 | |
| Novartis Pharmaceuticals Corporation | $24.19 | 2020 | |
| Exact Sciences Corporation | $23.88 | 2023 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $22.20 | 2025 | Quviviq |
| Mylan Specialty L.P. | $16.79 | 2021 | |
| Arbor Pharmaceuticals, INC. | $14.80 | 2021 | |
| Xeris Pharmaceuticals, INC. | $14.24 | 2025 | Keveyis |
| Upsher-Smith Laboratories LLC | $13.07 | 2019 | |
| Lundbeck LLC | $12.98 | 2023 | Vyepti |
| Biohaven Pharmaceuticals, INC. | $12.50 | 2021 | |
| Antares Pharma, INC. | $12.44 | 2020 | |
| Abbott Laboratories | $12.24 | 2021 | |
| Glaxosmithkline, LLC. | $11.59 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Schafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.